Galapagos raises EU1.2 million through warrant exercises
October 02 2015 - 4:16PM
Galapagos NV (Euronext & NASDAQ: GLPG) announced a share
capital increase arising from warrant exercises.
As a result of warrant exercises, Galapagos
issued 118,260 new ordinary shares on 25 September 2015,
for a total capital increase (including issuance premium) of
€1,198,094.00.
Pursuant to the rules of the warrant exercise
program of Galapagos' Executive Committee adopted in 2013,
Executive Committee members automatically are committed to exercise
a minimum number of warrants, subject to certain conditions.
Accordingly, CEO Onno van de Stolpe exercised 10,000 warrants and
two other Executive Committee members exercised an aggregate amount
of 5,000 warrants.
In accordance with Belgian transparency
legislation1, Galapagos notes that its total share capital
currently amounts to €211,045,322.22; the total number of
securities conferring voting rights is 39,012,842, which is also
the total number of voting rights (the "denominator"), and all
securities conferring voting rights and all voting rights are of
the same category. The total number of rights (warrants) to
subscribe to not yet issued securities conferring voting rights is
2,869,192, which equals the total number of voting rights that may
result from the exercise of these warrants. Galapagos does
not have any convertible bonds or shares without voting rights
outstanding.
About Galapagos Galapagos (Euronext &
NASDAQ: GLPG) is a clinical-stage biotechnology company specialized
in the discovery and development of small molecule medicines with
novel modes of action, with a pipeline comprising three Phase 2
programs, two Phase 1 trials, five pre-clinical studies, and 20
discovery small-molecule and antibody programs in cystic fibrosis,
inflammation, and other indications. Filgotinib is an
orally-available, selective inhibitor of JAK1 for the treatment of
rheumatoid arthritis and potentially other inflammatory diseases,
currently in Phase 2B studies in RA and in Phase 2 in Crohn's
disease. Galapagos reported good activity and a favorable safety
profile in both the DARWIN 1 and 2 trials in RA. In the field
of cystic fibrosis, AbbVie and Galapagos signed a collaboration
agreement to develop and commercialize molecules that address
mutations in the CFTR gene. Potentiator GLPG1837 is currently
in a Phase 1 trial, and corrector GLPG2222 is at the pre-clinical
candidate stage. GLPG1205, a first-in-class inhibitor of GPR84
and fully-owned by Galapagos, is currently being tested in a Phase
2 proof-of-concept trial in ulcerative colitis patients. GLPG1690,
a fully proprietary, first-in-class inhibitor of autotaxin, has
shown favorable safety in a Phase 1 trial and is expected to enter
Phase 2 in idiopathic pulmonary fibrosis. The Galapagos Group,
including fee-for-service subsidiary Fidelta, has approximately 400
employees, operating from its Mechelen, Belgium headquarters and
facilities in The Netherlands, France, and Croatia. More info at
www.glpg.com
CONTACT Galapagos NV Elizabeth Goodwin,
VP Corporate Communications & IR Tel: +1-781-460-1784
ir@glpg.com
Forward-looking statements This release may contain
forward-looking statements, all of which involve certain risks and
uncertainties. These statements are often, but are not always, made
through the use of words or phrases such as "believes,"
"anticipates," "expects," "intends," "plans," "seeks," "estimates,"
"may," "will," "could," "stands to," "continues," "we believe," "we
intend," as well as similar expressions. Such forward-looking
statements may involve known and unknown risks, uncertainties and
other factors which might cause the actual results, financial
condition, performance or achievements of Galapagos, or industry
results, to be materially different from any historic or future
results, financial conditions, performance or achievements
expressed or implied by such forward-looking statements. Among the
factors that may result in differences are the inherent
uncertainties associated with competitive developments, clinical
trial and product development activities, regulatory approval
requirements and estimating the commercial potential of our product
candidates. A further list and description of these risks,
uncertainties and other risks can be found in the company's
Securities and Exchange Commission filing and reports, including in
the company's prospectus filed with the SEC on May 14, 2015 and
future filings and reports by the company. Given these
uncertainties, the reader is advised not to place any undue
reliance on such forward-looking statements. These forward-looking
statements speak only as of the date of publication of this
document. Galapagos expressly disclaims any obligation to update
any such forward-looking statements in this document to reflect any
change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is
based, unless required by law or regulation.
1 Belgian Act of 2 May 2007 on the disclosure of
major shareholdings in issuers whose shares are admitted to trading
on a regulated market
HUG#1956421
Galapagos (EU:GLPG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Jul 2023 to Jul 2024